Sonoma Pharmaceuticals (NASDAQ:SNOA) Announces Earnings Results

Sonoma Pharmaceuticals (NASDAQ:SNOA) released its earnings results on Tuesday. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.19, Zacks reports. The business had revenue of $7.17 million during the quarter, compared to the consensus estimate of $5.29 million. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 21.41%.

Sonoma Pharmaceuticals Stock Performance

Shares of SNOA stock opened at $1.14 on Wednesday. Sonoma Pharmaceuticals has a 52 week low of $0.85 and a 52 week high of $3.95. The company has a market capitalization of $5.46 million, a price-to-earnings ratio of -0.93 and a beta of 1.31. The company has a 50-day simple moving average of $1.21 and a 200 day simple moving average of $1.65.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, Sonoma Pharmaceuticals currently has an average rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment. The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions. Products marketed under the company’s brands have included Dermacyn, for wound and skin care, and Ocucyn, for ophthalmic care, along with veterinary products and other prescription and over-the-counter formulations.